Out-of-Pocket Cost of Spinal Muscular Atrophy Gene Therapies Among Commercially Insured Patients
This cross-sectional study evaluates insurance and patient spending for the spinal muscular atrophy medications nusinersen, onasemnogene abeparvovec-xioi, and risdiplam from 2021 through 2022.
Authors
- Jeromie Ballreich (ORCID: https://orcid.org/0000-0003-2564-4577)
- Mariana P. Socal (ORCID: https://orcid.org/0000-0001-9459-4898)
- Gerard F. Anderson (ORCID: https://orcid.org/0000-0003-1845-1523)
- Ilina C. Odouard (ORCID: https://orcid.org/0009-0006-5431-3979)
- Maria Sckaff
Institutions
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
Publication Details
- Journal
- JAMA Pediatrics
- Published
- 2026-04-13
- DOI
- https://doi.org/10.1001/jamapediatrics.2026.0641
- Primary Topic
- Neurogenetic and Muscular Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00